Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format. The Orgenesis Point of Care (POCare) Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The Network brings together industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis is doing at www.orgenesis.com.
Shareholders and others will have the opportunity to engage with CEOs from AIM ImmunoTech, Heat Biologics, Avalon GloboCare, Oregenisis, and ImmunoPrecise Antibodies